je.st
news
Valeant seeing early impact on profits from acquisition of Bausch and Lomb
2014-02-27 23:30:03| Biotech - Topix.net
Valeant Pharmaceuticals International Inc. is reporting net income of $124 million for the fourth quarter of 2013, or 36 cents per diluted share.
Tags: early
impact
acquisition
profits
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||